4.7 Letter

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels

期刊

DIABETES CARE
卷 39, 期 3, 页码 E42-E43

出版社

AMER DIABETES ASSOC
DOI: 10.2337/dc15-2489

关键词

-

资金

  1. Novo Nordisk Fonden [NNF15OC0016484] Funding Source: researchfish

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Cardiac & Cardiovascular Systems

Lipids in CKD: What do we actually know?

Daniel Gordin, Petter Bjornstad, Daniel H. van Raalte

ATHEROSCLEROSIS (2022)

Article Pediatrics

Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes

Timothy Vigers, Carissa Vinovskis, Lu-Ping Li, Pottumarthi Prasad, Hiddo Heerspink, Angelo D'Alessandro, Julie A. Reisz, Federica Piani, David Z. Cherney, Daniel H. van Raalte, Kristen J. Nadeau, Meda E. Pavkov, Robert G. Nelson, Laura Pyle, Petter Bjornstad

Summary: This study compared plasma metabolites between youth with and without type 1 diabetes mellitus (T1DM) and found lower levels of metabolites associated with amino acid oxidation and the tricarboxylic acid cycle in individuals with T1DM. These metabolites were related to kidney function and may serve as potential biomarkers for improving kidney bioenergetics.

PEDIATRIC NEPHROLOGY (2023)

Article Endocrinology & Metabolism

Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial

Rosalie A. Scholtes, Charlotte M. Mosterd, Anne C. Hesp, Mark M. Smits, Hiddo J. L. Heerspink, Daniel H. van Raalte

Summary: This study investigated the effects of the SGLT2 inhibitor empagliflozin, the ARB losartan, and their combination on blood pressure. The results suggest that combination therapy has a greater blood pressure-lowering effect compared to monotherapy with either drug alone.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

Carel W. le Roux, Shuyu Zhang, Louis J. Aronne, Robert F. Kushner, Ariana M. Chao, Sriram Machineni, Julia Dunn, Farai B. Chigutsa, Nadia N. Ahmad, Mathijs C. Bunck

Summary: The SURMOUNT development program aims to evaluate the effectiveness and safety of tirzepatide as a treatment for obesity. The program includes four global phase 3 trials, which have shown that once-weekly administration of tirzepatide can significantly reduce body weight.

OBESITY (2023)

Article Multidisciplinary Sciences

Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes

Araz Rawshani, Darren K. McGuire, Elmir Omerovic, Naveed Sattar, John J. V. McMurray, Ulf Smith, Bjorn Redfors, Lennart Bergfeldt, Bjorn Eliasson, Jan Boren, Deepak L. Bhatt, Goran Bergstrom, Aidin Rawshani

Summary: This study investigated the association between type 2 diabetes and cardiac arrhythmias and conduction disturbances. The results showed that patients with diabetes had a higher risk of arrhythmias and conduction abnormalities, but among patients with all risk factors controlled within target range, the excess risk associated with diabetes was virtually not evident.

SCIENTIFIC REPORTS (2023)

Article Cardiac & Cardiovascular Systems

Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register

Bjorn Eliasson, Jan Ekelund, Cecilia Nagorny Holmberg, Michael Lyng Wolden, Kasper Sommer Matthiessen, Stefan James

Summary: This study compares the prescribing practices in Sweden with the 2021 ESC guidelines for cardiovascular protection in patients with type 2 diabetes. The analysis highlights the high incidence of major adverse cardiovascular events (MACE) in patients with a very high cardiovascular disease risk and suggests that prescribing cardiovascular-protective glucose-lowering medication, such as semaglutide, could potentially prevent a significant number of MACE.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study

Naveed Sattar, John McMurray, Jan Boren, Araz Rawshani, Elmir Omerovic, Niklas Berg, Janita Halminen, Kristoffer Skoglund, Bjorn Eliasson, Hertzel C. Gerstein, Darren K. McGuire, Deepak Bhatt, Aidin Rawshani

Summary: The goal of this study was to analyze the trends in cardiovascular events and cardiometabolic risk factor levels in individuals with type 2 diabetes (T2D) and matched control subjects. The results showed a decreasing trend in the risk and rates of atherosclerotic complications and heart failure in individuals with T2D, although the incidence of heart failure has plateaued in recent years. Modifiable risk factors within target levels were associated with lower risks for outcomes.

CIRCULATION (2023)

Letter Endocrinology & Metabolism

COMMENT ON BEZIN ET AL. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390

Mark M. Smits, Daniel H. van Raalte

DIABETES CARE (2023)

Article Cardiac & Cardiovascular Systems

Anaemia in patients with self-reported use of iron supplements in the BAriatric surgery SUbstitution and nutrition study: A prospective cohort study

Frida Lener, Gudrun Hoskuldsdottir, Kerstin Landin-Wilhelmsen, Cecilia Bjorkelund, Bjorn Eliasson, Lars Fandriks, Ville Wallenius, My Engstrom, Karin Mossberg

Summary: This study investigated the relationship between nutritional deficiencies and anaemia in patients who reported use of supplementation two years after bariatric surgery versus patients who do not. The results indicated that iron deficiency or anaemia may not be prevented by substitutional treatment per current guidelines after bariatric surgery and highlights there is reason to ensure adequate preoperative micronutrient levels.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2023)

Review Cell Biology

The impact of cellular senescence in human adipose tissue

Annika Nerstedt, Ulf Smith

Summary: In recent years, there has been a significant increase in the prevalence of obesity, leading to a growing interest in adipose tissue as a metabolically dynamic and endocrine organ. Obesity can lead to the development of metabolic diseases such as type 2 diabetes. Cellular senescence, a mechanism of aging, has been found to play a role in metabolic tissues and age-related conditions, including obesity.

JOURNAL OF CELL COMMUNICATION AND SIGNALING (2023)

Article Cell Biology

Report on the 11th international workshop on the CCN family of genes, Nice, October 20-24, 2022

Havard Attramadal, Sushanta K. Banerjee, Brahim Chaqour, Gary Fisher, Lester Lau, Bernard Perbal, Ulf Smith, Herman Yeger

Summary: To celebrate the 20th anniversary of the CCN society and hold the first post-Covid-19 live meeting, the ICCNS executive board chose Nice as the venue for the 11th International workshop on the CCN family of genes. Colleagues from other cell signaling fields were invited to present their work overview and future directions of their laboratory. Additionally, the JCCS Editorial Board members were invited to a special session for open discussions on all aspects of the journal.

JOURNAL OF CELL COMMUNICATION AND SIGNALING (2023)

Review Endocrinology & Metabolism

Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?

Mark M. Smits, Jens J. Holst

Summary: In recent years, the beneficial effects of GLP-1 receptor agonists have been observed, such as reducing cardiovascular risk in patients with type 2 diabetes and body weight in those with obesity. However, there are differences in their routes of action compared to endogenous GLP-1. It may be useful to develop agents that stimulate GLP-1 release in order to overcome the limitations of GLP-1 receptor agonists.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2023)

Article Cardiac & Cardiovascular Systems

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)

Nikolaus Marx, Massimo Federici, Katharina Schuett, Dirk Mueller-Wieland, Ramzi A. Ajjan, Manuel J. Antunes, Ruxandra M. Christodorescu, Carolyn Crawford, Emanuele Di Angelantonio, Bjorn Eliasson, Christine Espinola-Klein, Laurent Fauchier, Martin Halle, William G. Herrington, Alexandra Kautzky-Willer, Ekaterini Lambrinou, Maciej Lesiak, Maddalena Lettino, Darren K. Mcguire, Wilfried Mullens, Bianca Rocca, Naveed Sattar

EUROPEAN HEART JOURNAL (2023)

Review Medicine, Research & Experimental

Increased cell senescence in human metabolic disorders

Rosa Spinelli, Ritesh Kumar Baboota, Silvia Gogg, Francesco Beguinot, Matthias Bluher, Annika Nerstedt, Ulf Smith

Summary: Cell senescence (CS) plays a crucial role in the connection between aging and chronic disorders, and CS is more prevalent in major metabolic tissues with aging. However, CS is also increased in adult obesity, type 2 diabetes (T2D), and nonalcoholic fatty liver disease, regardless of aging. Dysfunction and inflammation are common features of senescent tissues, affecting both progenitor cells and mature differentiated cells. Recent studies have found that hyperinsulinemia and insulin resistance (IR) can promote CS in human adipose and liver cells. Conversely, increased CS also promotes cellular IR, indicating their interdependence. Additionally, increased adipose CS in T2D is not solely determined by age, BMI, or hyperinsulinemia, suggesting premature aging. These findings suggest that senomorphic/senolytic therapy could be important for treating common metabolic disorders.

JOURNAL OF CLINICAL INVESTIGATION (2023)

暂无数据